Abstract：
Renal transplantation represents the foremost efficacious approach for ameliorating end-stage renal disease. Despite the current state of advanced renal transplantation techniques and the established postoperative immunosuppression strategy, a subset of patients continues to experience immune rejection during both the early and late postoperative phases, ultimately leading to graft loss. Consequently, the identification of immunobiomarkers capable of predicting the onset of immune rejection becomes imperative in order to facilitate early intervention strategies and enhance long-term prognoses. Upon reviewing the pertinent literature, we identified several indicators that could potentially serve as immune biomarkers to varying extents. These include the T1/T2 ratio, Treg/Th17 ratio, IL-10/TNF-α ratio, IL-33, IL-34, IL-6, IL-4, other cytokines, and NOX2/4.
摘要：
肾移植是改善终末期肾病的最有效方法。尽管目前有先进的肾移植技术和既定的术后免疫抑制策略，一部分患者在术后早期和晚期都会持续经历免疫排斥反应，最终导致嫁接损失。因此,为了促进早期干预策略和提高长期预后,鉴定能够预测免疫排斥反应发生的免疫生物标志物变得必要.在回顾相关文献后，我们确定了几种可能在不同程度上作为免疫生物标志物的指标.这些包括T1/T2比，Treg/Th17比值,IL-10/TNF-α比值，IL-33，IL-34，IL-6，IL-4，其他细胞因子，NOX2/4
